Form 4: Director Acquires Shares in Inhibitor Therapeutics

Niraj Vasisht, a Director at Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock as compensation.

Summary

• Niraj Vasisht, a Director of Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock on May 5, 2026.
• These shares were issued as compensation under the Issuer's 2025 Equity Incentive Plan.
• The acquisition was made at a price of $0, indicating it was a grant or award.
• Following this transaction, Vasisht beneficially owns 200,000 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation-related stock award to a director rather than a significant financial event or strategic shift.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The issuance of shares as compensation aligns management incentives with shareholder value.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that director stock awards are common in the biotechnology and pharmaceutical sectors as a means to attract and retain talent and align executive compensation with long-term company performance.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, but it does not represent a new capital injection or change in company strategy.

Key Dates

Keywords

Inhibitor Therapeutics, INTI, Form 4, Director, Stock Award, Equity Incentive Plan, Beneficial Ownership